MedTrace Logo

Placebo-Controlled Study Assessing the Use of a Novel Exfoliative Serum With A Chemical Peel to Improve Photodamage in Adults

NCT05908825 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-07-19

No results posted yet for this study

Summary

This is a split-face, double-blind, placebo-controlled study assessing the use of a novel exfoliative serum with a chemical peel to improve photodamage in healthy female subjects between the ages of 30 and 65 years, inclusive, with Fitzpatrick skin types I-VI.

Conditions

  • Photodamaged Skin

Interventions

DRUG

Vitamin C with AHA Exfoliative Serum

Catalyst is a novel skincare product comprised of low concentrations of multiple hydroxy acids and will be randomly assigned as Product A or Product B to be applied to one side of the face.

DRUG

Placebo serum

Placebo serum will be randomly assigned as Product A or Product B to be applied to one side of the face.

Sponsors & Collaborators

  • SkinCeuticals

    collaborator UNKNOWN

  • Austin Institute for Clinical Research

    lead NETWORK

Principal Investigators

  • Edward Lain, MD, MBA · Austin Institute for Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-22
Primary Completion
2023-11-16
Completion
2024-01-26

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05908825 on ClinicalTrials.gov